Blood sugar increased; Blood cholesterol increased; Upset stomach; Pain in arm; Headache; Increased LDL; Triglyceride increased; Petechiae; This is a spontaneous report from a non-contactable consumer (patient). A 67-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, lot number was not reported, expiration date was not reported), via intramuscular on an unspecified date as dose 1, single and received second dose of BNT162B2 (lot number was not reported, expiration date was not reported), via an unspecified route of administration on an unspecified date as dose 2, single for covid-19 immunization. The patient also received ibrutinib (IMBRUVICA, Batch/Lot number was not reported, oral, 140 mg, 1x/day, 280 mg, 1x/day) from Jan2020 and ongoing for small lymphocytic lymphoma and received butalbital, caffeine, paracetamol (FIORICET, Batch/Lot number was not reported, Taking 1 Capsule As Needed Instead Of The Prescribed 2 Capsules), via an unspecified route of administration from an unspecified date to an unspecified date for migraine. The patient medical history included non smoker, osteoarthritis, osteoporosis, migraines, fibromyalgia, borderline low density lipoprotein, boderline triglyceride, non alcohol user, lymphocytic lymphoma. Concomitant medication included duloxetine hydrochloride (CYMBALTA, 60 mg, 1x/day) taken for fibromyalgia from Oct2010 and ongoing. The patient previously took codeine [codeine phosphate] and experienced codeine allergy. It was reported that the patient experienced increased LDL, triglyceride increased on 22Apr2021, blood sugar increased, blood cholesterol increased, upset stomach, pain in arm, headache on an unspecified date, petechiae on Jan2021. The patient underwent lab tests and procedures which included ALT (alanine aminotransferase): 13   on 22Apr2021, anion gap: 8  on 22Apr2021, AST (aspartate aminotransferase): 17 on 22Apr2021, absolute basophils (basophil count): 0.04 on 22Apr2021, basophils (basophil count): 0 on 22Apr2021, albumin (blood albumin): 4.0 on 22Apr2021, ALP (blood alkaline phosphatase): 41 on 22Apr2021, bilirubin (blood bilirubin): 0.5 on 22Apr2021, calcium (blood calcium): 9.2 on 22Apr2021 , chloride (blood chloride): 102 on 22Apr2021, creatinine (blood creatinine): 0.65 on 22Apr2021, glucose (blood glucose): 97 on 22Apr2021, blood potassium: 4.2 on 22Apr2021, blood sodium: 138   on 22Apr2021, (triglycerides) blood triglycerides: 316 mg/dl on 22Apr2021, BUN (Blood urea): 18 on 22Apr2021, Carbon dioxide: 28 on 22Apr2021, Eosinophils (Eosinophil count): 1 on 22Apr2021, Eosinophils absolute (Eosinophil count): 0.2 on 22Apr2021, Glomerular filtration rate: greater than 60 on 22Apr2021, A1C (Glycosylated haemoglobin): 5.9 %on 22Apr2021, Haematocrit: 37.5 on 22Apr2021, Haemoglobin: 12.1 on 22Apr2021, LDL (Low density lipoprotein): 102 mg/dl on 22Apr2021, Lymphocytes (Lymphocyte count): 83 on 22Apr2021, MCHC (Mean cell haemoglobin concentration): 22.3 on 22Apr2021, MCV (Mean cell volume): 87.4 on 22Apr2021, monocytes (Monocyte count): 3 on 22Apr2021, Neutrophils (Neutrophil count): 2.81 on 22Apr2021, Platelets (Platelet count): 251 on 22Apr2021, RBC (Red blood cell count): 4.29 on 22Apr2021, RDW (Red cell distribution width): 14.4, 11.2 on 22Apr2021, Total CHOLESTEROL (Total cholesterol/HDL ratio): 215 mg/dl on 22Apr2021, Vitamin D: 38 mg/dl on 22Apr2021, WBC (White blood cell count): 28.5 on 22Apr2021, HDL (High density lipoprotein): 50 mg/dl on 22Apr2021, Monocytes Absolute (Monocyte count): 17.6  on 22Apr2021, Non high density lipoprotein (high density lipoprotein): 165 mg/dl on 22Apr2021. The reporters causality for the drugs (Imbruvica (Ibrutinib), Covid19 Vaccine) and events of elevated Ldl, elevated triglycerides, increased blood sugar, increased cholesterol, petechiae, upset stomach, sore arm and headache was not provided. The reporters causality for the drug (Fioricet(Butalbital;Caffeine;Paracetamol)(Capsule)(Caffeine, Butalbital, Paracetamol),Unknown)and events of elevated Ldl, elevated triglycerides, increased blood sugar, increased cholesterol, petechiae, sore arm and headache was not provided and upset stomach was possible. The action taken in response to the event(s), for ibrutinib was not applicable, for butalbital, caffeine, paracetamol was not applicable. The outcome of the event petechiae was recovered on Jan2021, upset stomach, pain in arm, headache was recovered on an unspecified date, outcome for events increased LDL, triglyceride increased was not recovered and outcome was unknown for other events.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.